Continuous Manufacturing Market Outlook 2026–2036: Market Size, Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast for Pharma and CDMOs — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how continuous manufacturing, meaning the production of drug substances and products in an uninterrupted flow monitored by real-time analytics instead of in separate batches, moves from a niche to a mainstream mode of pharmaceutical production over the next ten years. The change runs from the reactor and tablet press to the regulatory file, and it reshapes how drugs are made, released and supplied.

The case begins with the batch. A conventional process makes a drug in steps, holds material between them, tests at the end and often discards a batch that fails. A continuous process feeds material through connected steps and measures quality as it goes. One trade source reports that a continuous facility can reduce the space required by up to 70% compared with a batch plant. This is a general claim without a named site, but it shows why capital, speed and supply resilience are in play.

The first proof is regulatory acceptance. At an FDA education meeting on 20 May 2026, Adam Fisher, staff director in the Office of Pharmaceutical Quality at CDER, reported that the agency has approved 17 drugs made using continuous manufacturing. The first was Vertex Pharmaceuticals Orkambi in July 2015. Seventeen approvals in under eleven years shows that the route is proven, and that it has so far been used for a limited set of products.

The second proof is the pipeline of ideas. Of 191 applications accepted into the FDA Emerging Technology Program since 2014, 72 are for continuous manufacturing, which Fisher called the most widely accepted technology in the programme. The FDA also described the statutory Advanced Manufacturing Technologies designation created by the Food and Drug Omnibus Reform Act of 2022. A programme in which continuous processes lead the list tells makers that the regulator expects more filings of this kind.

Policy and supply security add momentum. On 29 June 2026 the FDA announced seven participants in its PreCheck Pilot Program for new US drug manufacturing facilities, including Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, and published a revised pre-approval inspection compliance program. New plants are being designed now, and plants designed now can choose continuous and digital operation from the start.

The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players and the adoption trajectory to 2036.

It is a focused 109-page decision brief for pharmaceutical manufacturers, contract development and manufacturing organisations, equipment and analytics suppliers, investors and policy makers. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which products and modalities convert first, how regulation and plant investment sequence demand, and who captures value as pharmaceutical production becomes continuous and data-driven.

A continuous pharmaceutical process links steps that are normally separate. For solid dose products, powders are fed, blended, granulated or directly compressed and coated in one line. For small molecule drug substances, flow reactors replace large stirred tanks. Material moves through at a steady rate, and the line runs for hours or days instead of finishing in a batch.

Process analytical technology is what makes this safe. Spectroscopic and other sensors measure composition and other attributes in the stream, and control software adjusts feed rates to keep the product within limits. If the process drifts, the affected material can be diverted. This allows quality to be built in during production, and it supports release based on process data rather than on end-product testing.

The regulatory base is in place. The ICH Q13 guideline sets expectations for continuous manufacturing of drug substances and drug products, and the FDA runs the Emerging Technology Program and the statutory Advanced Manufacturing Technologies designation to give sponsors early engagement. In January 2025 the FDA also issued a draft guidance on advanced approaches to pharmaceutical manufacturing. Early dialogue reduces the risk that a novel line is questioned late in review.

Digital tools extend the model. Digital twins simulate the line, models predict the effect of a change in raw material, and the FDA CDER guidance agenda for 2026 lists a planned draft on quality considerations for AI and machine learning in manufacturing. Industry 4.0 in pharmaceutical production therefore means connected equipment, models and data under a quality system, not only automation.

The constraints are capital, cost of change and fit. Existing batch plants are depreciated and validated, so switching has a cost. Not every product suits continuous processing, and biologics are harder than small molecules. Skills in process control and data science are scarce. Regulatory expectations for control strategy and material traceability are demanding. The decade turns on whether new plants choose continuous by default and whether contract manufacturers make it a standard service.

The continuous manufacturing market, covering continuous production equipment, process analytical technology, automation and control software, and related engineering and contract services for pharmaceutical drug substances and drug products, and excluding conventional batch equipment, general laboratory instruments and non-pharmaceutical continuous processing, is valued at USD 3–4 billion in 2026 and is projected to reach USD 11–15 billion by 2036, at a CAGR of 14%.

The 2026 base rests on continuous lines at large manufacturers, process analytical technology bought for both batch and continuous use, control and data software, and engineering services. From that base, growth follows the choice of continuous at new plants and the conversion of selected products. As more products are approved on continuous lines, each filing gives later sponsors a precedent, and equipment and analytics makers benefit from repeat orders.

The forecast is sensitive to regulatory support, the pace of new plant construction and the readiness of continuous processes for biologics. Regionally, North America leads on regulatory programmes and new plant investment, Europe on equipment makers and guideline development, and Asia-Pacific on generic and contract manufacturing capacity.

The base case assumes steady regulatory support, new plant construction in North America and Europe and gradual maturity of continuous processes for complex molecules, giving the inflection around 2031. An accelerated case adds strong policy incentives for domestic manufacturing and rapid conversion of products, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes slow plant investment and technical difficulty for biologics, holding growth at the bottom of the range.

Growth drivers

• Regulatory push: 17 approvals using continuous manufacturing and 72 continuous applications in the Emerging Technology Program.
• Supply security and domestic manufacturing policy, including the PreCheck Pilot Program announced in June 2026.
• Smaller footprint, faster production and less waste than batch plants.
• Digital and AI tools for real-time control and release.

Enablers

• ICH Q13 guideline on continuous manufacturing.
• Statutory Advanced Manufacturing Technologies designation and the Emerging Technology Program.
• Maturing process analytical technology and control software.
• CDMOs that provide shared continuous capacity.

Restraints and barriers

• Capital tied up in validated batch plants.
• Process complexity for biologics and some products.
• Shortage of process control and data science skills.
• Demanding expectations for control strategy and material traceability.

Five converging forces will determine how fast continuous manufacturing scales.

(1) Regulatory acceptance and incentives. (2) New plant investment and supply security policy. (3) Process analytical technology and digital control. (4) Contract manufacturing capacity. (5) Technical readiness for complex molecules. The brief assesses each force for direction, speed and confidence.

The key players operating in pharmaceutical continuous manufacturing include Vertex Pharmaceuticals Incorporated, Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., Novartis AG, GSK plc, Merck & Co., Inc., Sanofi, AstraZeneca PLC, Amneal Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Cellares Corporation, Fujifilm Holdings Corporation, Kyowa Kirin Co., Ltd., Lonza Group AG, Thermo Fisher Scientific Inc., Cambrex Corporation, Siegfried Holding AG, Piramal Pharma Limited, Olon S.p.A., Samsung Biologics Co., Ltd., GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Coperion GmbH, Fette Compacting GmbH, Gericke AG, Continuus Pharmaceuticals, Inc., Corning Incorporated, Syrris Ltd, Vapourtec Ltd, Sartorius AG, Cytiva, Repligen Corporation, Merck KGaA, Siemens AG, Emerson Electric Co., Yokogawa Electric Corporation, Mettler-Toledo International Inc., Bruker Corporation, the US Food and Drug Administration, the European Medicines Agency, the International Council for Harmonisation, the International Society for Pharmaceutical Engineering and the United States Pharmacopeia.

The brief profiles representative players in each archetype and assesses which are positioned to supply continuous capacity and technology.

The competitive landscape is forming around six archetypes. Originator pharmaceutical manufacturers. Contract development and manufacturing organisations. Continuous equipment makers. Process analytical technology and instrument suppliers. Automation and software providers. Regulators and standard-setters. Competitive intensity is high in 2026 and is expected to rise as plant investment and regulatory support lift demand through 2031.

Where value migrates.

In 2026 value sits in continuous equipment and analytical instruments for lead products. By 2031 it moves to integrated lines, control and digital twin software, and contract capacity that offers continuous as a standard service. By 2036 it settles in platform suppliers with validated modular lines, data and software that support real-time release, and CDMOs with shared capacity. Standalone batch equipment loses standing in new plants.

The signals converge on acceptance and new plants. Approvals using continuous manufacturing number 17. Applications to the Emerging Technology Program favour continuous processes, with 72 of 191. New facility programmes are underway, with seven PreCheck participants. Guidance agendas include AI and distributed manufacturing. Each signal moves continuous manufacturing from an exception to an expected option in plant design.

Research and patent activity reflects where the chain is weakest: continuous processing of biologics, in-line measurement of complex attributes, material traceability across a continuous line and models that predict process drift. The brief therefore tracks four indicators: the number of products approved on continuous lines, the share of new plants designed as continuous, the number of real-time release approvals and the capacity offered by contract manufacturers.

Regionally, North America leads on regulatory programmes and new plant investment, Europe on equipment makers and guideline development, and Asia-Pacific on generic and contract manufacturing. Oral solid dose, small molecule drug substances, biologics and cell and gene therapy manufacturing are the demand pools in that order.